Kendall Park, NJ, United States of America

Kothandaraman Shankaran


Average Co-Inventor Count = 5.9

ph-index = 5

Forward Citations = 151(Granted Patents)


Location History:

  • Edison, NJ (US) (1999)
  • Kendall Park, NJ (US) (1997 - 2009)

Company Filing History:


Years Active: 1997-2009

Loading Chart...
7 patents (USPTO):Explore Patents

Of course! Here is the article about inventor Kothandaraman Shankaran:

Title: The Inventor Profile: Kothandaraman Shankaran

Introduction:

Kothandaraman Shankaran is a renowned inventor based in Kendall Park, NJ, US, with an impressive portfolio of 7 patents under his belt. His innovative work focuses on developing compounds that serve as modulators of chemokine receptor activity to address various health conditions.

Latest Patents:

Shankaran's latest patents showcase his dedication to advancing treatments for inflammatory and immunoregulatory disorders. One of his inventions includes 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity. These compounds demonstrate utility in preventing or treating conditions such as allergic diseases, autoimmune pathologies, and more.

Career Highlights:

Currently affiliated with Merck & Company, Inc., Shankaran's contributions have significantly impacted the pharmaceutical industry. His expertise in developing novel compounds reflects his commitment to improving healthcare outcomes globally.

Collaborations:

Shankaran's collaborative spirit is evident through his work with esteemed colleagues Shrenik K Shah and Charles G Caldwell. Together, they contribute to the advancement of pharmaceutical research and the development of cutting-edge therapies.

Conclusion:

In conclusion, Kothandaraman Shankaran stands as a beacon of innovation in the field of pharmaceuticals, with a track record of pioneering patents that have the potential to revolutionize the treatment of various health conditions. His continued efforts exemplify a commitment to driving positive change through groundbreaking inventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…